OBJECTIVESdEvaluate ITCA 650, a continuous subcutaneous miniature osmotic pump delivery system of exenatide versus twice-daily exenatide injections (Ex-BID) in subjects with type 2 diabetes. RESEARCHDESIGNANDMETHODSdRandomized, two-stage, 24-week, open-label, phase 2 study in type 2 diabetes inadequately controlled with metformin. Stage I: 155 subjects were randomized to 20 or 40 mg/day of ITCA 650 or Ex-BID 5→10 mg. Stage II: 131 subjects were rerandomized to 20, 40, 60, or 80 mg/day of ITCA 650. Change from baseline for HbA1c, weight, and fasting plasma glucose were evaluated at weeks 12 and 24. RESULTSdHbA1c was significantly lower in all groups after 12 and 24 weeks. Stage I: mean change in HbA1c from a mean baseline of 7.9–8.0 % was20....
OBJECTIVE: Traditional blood glucose-lowering agents do not sustain adequate glycemic control in mos...
Aims: To evaluate the efficacy of exenatide in Asian patients with type 2 diabetes (T2D) inadequatel...
Background Incretin-based therapies provide additional options for treating type 2 diabetes. We aime...
OBJECTIVEdTo evaluate ITCA 650, a continuous subcutaneous miniature osmotic pump delivery system of ...
AbstractAimsEvaluate the efficacy and tolerability of ITCA 650 in subjects with type 2 diabetes trea...
AbstractBackgroundExenatide, a glucagon-like peptide-1 receptor agonist administered by self-injecti...
OBJECTIVE ITCA 650 (exenatide in osmotic mini-pump) continuously delivers exenatide subcutaneously f...
OBJECTIVE: To test the safety and efficacy of exenatide once weekly (EQW) compared with metformin (...
injections for patients with type 2 diabetes mellitus who have poor glycemic control despite taking ...
OBJECTIVE — This study evaluates the ability of the incretin mimetic exenatide (exendin-4) to improv...
OBJECTIVE — This study evaluated the effects of exenatide, a novel incretin mimetic, in hyperglycemi...
Peggy Soule Odegard1, Anthony DeSantis21School of Pharmacy, 2Division of Metabolism, Endocrinology a...
AIM: The study objective was to analyze, in everyday practice, the long-term metabolic effects of ex...
Aims: To evaluate the efficacy of exenatide in Asian patients with type 2 diabetes (T2D) inadequate...
Abstract: Type 2 diabetes (T2DM) is a disease of epidemic proportion associated with significant mor...
OBJECTIVE: Traditional blood glucose-lowering agents do not sustain adequate glycemic control in mos...
Aims: To evaluate the efficacy of exenatide in Asian patients with type 2 diabetes (T2D) inadequatel...
Background Incretin-based therapies provide additional options for treating type 2 diabetes. We aime...
OBJECTIVEdTo evaluate ITCA 650, a continuous subcutaneous miniature osmotic pump delivery system of ...
AbstractAimsEvaluate the efficacy and tolerability of ITCA 650 in subjects with type 2 diabetes trea...
AbstractBackgroundExenatide, a glucagon-like peptide-1 receptor agonist administered by self-injecti...
OBJECTIVE ITCA 650 (exenatide in osmotic mini-pump) continuously delivers exenatide subcutaneously f...
OBJECTIVE: To test the safety and efficacy of exenatide once weekly (EQW) compared with metformin (...
injections for patients with type 2 diabetes mellitus who have poor glycemic control despite taking ...
OBJECTIVE — This study evaluates the ability of the incretin mimetic exenatide (exendin-4) to improv...
OBJECTIVE — This study evaluated the effects of exenatide, a novel incretin mimetic, in hyperglycemi...
Peggy Soule Odegard1, Anthony DeSantis21School of Pharmacy, 2Division of Metabolism, Endocrinology a...
AIM: The study objective was to analyze, in everyday practice, the long-term metabolic effects of ex...
Aims: To evaluate the efficacy of exenatide in Asian patients with type 2 diabetes (T2D) inadequate...
Abstract: Type 2 diabetes (T2DM) is a disease of epidemic proportion associated with significant mor...
OBJECTIVE: Traditional blood glucose-lowering agents do not sustain adequate glycemic control in mos...
Aims: To evaluate the efficacy of exenatide in Asian patients with type 2 diabetes (T2D) inadequatel...
Background Incretin-based therapies provide additional options for treating type 2 diabetes. We aime...